Relay Therapeutics Inc Aktie News

Die zulassungsrelevante Phase‑3‑Studie ReDiscover‑2 in der Zweitlinientherapie von Brustkrebs wird voraussichtlich Mitte 2027 die Einschreibung abschließen Aktualisierte Daten aus der laufenden Phase‑1/2‑Studie ReInspire von zovegalisib bei Gefäßanomalien werden in einem mündlichen Vortrag auf dem 68. Jahreskongress und Ausstellung der American Society of Hematology (ASH) vorgestellt; Relay wir...

Nach einem Anstieg von 1.027 % vom Tief setzt Relay Therapeutics KI und maschinelles Lernen ein, um weitere Gewinne zu befeuern.

Ausgewählt: z ovegalisib plus atirmociclib als künftiges Triplet-Regime für die Erstlinienbehandlung von Brustkrebs; eine Phase‑3‑Erstlinienstudie bei endokrinsensiblen Patientinnen wird voraussichtlich Anfang 2027 initiiert, vorbehaltlich behördlicher Rückmeldungen

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday...

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per ...

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also inte...

Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink vascular malformations and improve symptoms ​in patients with rare vascular disorders.

Relay Therapeutics wiped the floor Tuesday with Wall Street's expectations for its experimental vascular anomalies treatment.